N.E.W. Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History

N.E.W. Advisory Services’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$624	Hold	1	–	–	﹤0.01%	965
2026 Q1	$773	Hold	1	–	–	﹤0.01%	890
2025 Q4	$772	Hold	1	–	–	﹤0.01%	866
2025 Q3	$562	Hold	1	–	–	﹤0.01%	837
2025 Q2	$525	Sell	1 -1	-50%	-$558	﹤0.01%	837
2025 Q1	$1.27K	Buy	+2	New	+$1.38K	﹤0.01%	838

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

N.E.W. Advisory Services's REGN Position: Q2 2026 in Review

N.E.W. Advisory Services held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 1 share worth $624. The position accounts for ﹤0.01% of the portfolio, ranked #965.

N.E.W. Advisory Services first reported a position in REGN in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.27K in Q1 2025. 844 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

N.E.W. Advisory Services held 1 share of Regeneron Pharmaceuticals worth $624 as of Q2 2026.
N.E.W. Advisory Services left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of N.E.W. Advisory Services's portfolio in Q2 2026, its #965 holding.
N.E.W. Advisory Services first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
N.E.W. Advisory Services's Regeneron Pharmaceuticals position peaked at $1.27K in Q1 2025.
844 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on N.E.W. Advisory Services's 13F filing for Q2 2026, filed 6 Aug 2026.